Gain Therapeutics, Inc. (GANX) Free Cash Flow
Gain Therapeutics, Inc. (GANX) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2021-12-31 | -$12.46M |
| 2022-12-31 | -$14.81M |
| 2023-12-31 | -$18.88M |
| 2024-12-31 | -$18.90M |
| 2025-12-31 | -$18.47M |
How GANX compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| SPRO | Spero Therapeutics Inc. | -$12.62M |
| RFL | Rafael Holdings Inc. Class B | -$18.95M |
| STIM | Neuronetics Inc. | -$21.18M |
| INMB | INmune Bio Inc. | -$23.64M |
| MYGN | Myriad Genetics Inc. | -$25.60M |
These are five companies in the same sector as GANX with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Gain Therapeutics, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("GANX", 2025, "")
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | GANX | $1.64 | +1.55% | 0.33M |
| 3 | ||||
| 4 | ||||
| 5 |